IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR) reported a net loss of $3,635,000, or $0.10 per share for the quarter ended September 30, 2006 compared with a net loss of $2,530,000, or $0.08 per share for the corresponding prior year period. For the nine months ended September 30, 2006, Cortex reported a net loss of $12,592,000, or $0.37 per share compared to a net loss of $7,867,000, or $0.24 per share for the corresponding prior year period. For both current year periods, operating expenses include non-cash stock compensation charges and amounts related to addressing the earlier clinical hold on Cortex’s AMPAKINE® CX717 by the U.S. Food and Drug Administration (“FDA”).
